According to a recent LinkedIn post from Colossal Biosciences, the company is highlighting a new de-extinction effort focused on the bluebuck, a slate-blue antelope native to South Africa that disappeared around 1800. The post indicates that Colossal has produced a high-quality genome for the species and is developing assisted reproductive tools for antelope, positioning this initiative as both a de-extinction milestone and a platform for broader conservation technologies.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that many of these reproductive tools are novel in antelope and could eventually be applied to address habitat fragmentation and declining genetic diversity in living antelope populations across Africa. For investors, this points to continued expansion of Colossal’s IP portfolio in genomics and reproductive biotech, potentially enhancing its long-term commercialization prospects in conservation technology, wildlife genetics, and adjacent agricultural or veterinary applications.
By tying the bluebuck project to practical benefits for endangered and existing species, the LinkedIn content implicitly frames de-extinction as a driver of marketable tools rather than a standalone scientific showcase. If successful, such platform technologies could support future partnerships with conservation organizations, governments, and agribusiness, which may strengthen Colossal’s positioning in the emerging de-extinction and biodiversity technology segment.